GR1010195B - Protection against covid-19 - Google Patents
Protection against covid-19 Download PDFInfo
- Publication number
- GR1010195B GR1010195B GR20200100756A GR20200100756A GR1010195B GR 1010195 B GR1010195 B GR 1010195B GR 20200100756 A GR20200100756 A GR 20200100756A GR 20200100756 A GR20200100756 A GR 20200100756A GR 1010195 B GR1010195 B GR 1010195B
- Authority
- GR
- Greece
- Prior art keywords
- ointment
- covid
- protection against
- monoclonal
- combination
- Prior art date
Links
- 208000025721 COVID-19 Diseases 0.000 title description 8
- 239000002674 ointment Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008311 hydrophilic ointment Substances 0.000 abstract description 3
- 241000711573 Coronaviridae Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- KJLPSBMDOIVXSN-UHFFFAOYSA-N 4-[4-[2-[4-(3,4-dicarboxyphenoxy)phenyl]propan-2-yl]phenoxy]phthalic acid Chemical compound C=1C=C(OC=2C=C(C(C(O)=O)=CC=2)C(O)=O)C=CC=1C(C)(C)C(C=C1)=CC=C1OC1=CC=C(C(O)=O)C(C(O)=O)=C1 KJLPSBMDOIVXSN-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
ΠΡΟΣΤΑΣΙΑ ΤΗΣ ΜΟΛΥΝΣΗΣ ΤΩΝ ΑΤΟΜΩΝ ΑΠΟ ΤΟΝ ΚΟΡΩΝΟΪΌ COVID-19 PROTECTION OF PEOPLE FROM INFECTION FROM CORONAVIRUS COVID-19
ΥΠΟΔΟΜΗ ΤΗΣ ΕΦΕΥΡΕΣΗΣ BACKGROUND OF THE INVENTION
Πεδίο της εφεύρεσης Field of invention
Η Πανδημία με αίτιο τον COVID-19 έχει στοιχήσει πολλές ανθρώπινες ζωές χωρίς ακόμα να έχει βρεθεί ένα αποτελεσματικό φάρμακο για τη αντιμετώπισή του. The Pandemic caused by COVID-19 has claimed many human lives without an effective drug to treat it yet being found.
Τελευταία η τάση είναι η εφαρμογή αποτελεσματικών εμβολίων με μία γιγαντιαία προσπάθεια για τον εμβολιασμό όσο το δυνατόν περισσότερων ατόμων ώστε να αποτραπεί η μετάδοση του κορωνοϊού COVID-19 που πρέπει βέβαια να εμβολιαστεί το 70 % για να εξοντωθεί ο ιός. The latest trend is the implementation of effective vaccines with a gigantic effort to vaccinate as many people as possible to prevent the transmission of the COVID-19 coronavirus, of course 70% must be vaccinated to eradicate the virus.
Πιθανά σε ορισμένες χώρες να πραγματοποιηθεί ο εμβολιασμός σε αυτό το ποσοστό όμως θα είναι δύσκολο σε παγκόσμια κλίμακα να είναι δυνατό. It is possible in some countries to vaccinate at this rate, but it will be difficult on a global scale to be possible.
Έτσι οι χώρες αναγκάζονται να μπουν σε lockdown για το περιορισμό των κρουσμάτων. So the countries are forced to go into lockdown to limit the cases.
Επιπλέον, η εφαρμογή στις χώρες του lockdown έχει δραματικές οικονομικές επιπτώσεις. In addition, the implementation in the countries of the lockdown has dramatic economic consequences.
Η παρούσα εφεύρεση αποτελεί μια απλή και φτηνή μέθοδο για την αποτελεσματική προστασία της μόλυνσης των ατόμων από τον κορωνοϊό COVID-19. The present invention is a simple and inexpensive method for the effective protection of individuals from infection with the COVID-19 coronavirus.
Περιγραφή της μεθόδου Description of the method
Η μετάδοση του κορωνοϊού COVID-19 γίνεται σε ένα μεγάλο ποσοστό από τον βήχα και την ομιλία του θετικού ατόμου μέσω της μύτης κατά κύριο ποσοστό του άλλου ατόμου. The transmission of the corona virus COVID-19 occurs to a large extent by the coughing and speaking of the positive person through the nose mainly of the other person.
Έτσι η παραγωγή μιας αλοιφής που περιέχει μια υδρόφιλη αλοιφή σε συνδυασμό με μια περιεκτικότητα ενός polyreactive μονοκλονικού ή ενός κλασικού μονοκλονικού αντισώματος σε ποσοστό στο 10% περίπου θα μπορούσε να δρα αποτελεσματικά για την προστασία των ατόμων από την μολυσματική ασθένεια COVID-19. Thus the production of an ointment containing a hydrophilic ointment in combination with a content of a polyreactive monoclonal or a classical monoclonal antibody at a rate of about 10% could act effectively to protect individuals from the infectious disease COVID-19.
Η τελική αλοιφή θα τοποθετηθεί με το δάκτυλο που θα είναι πλυμένο με νερό και σαπούνι στη μύτη και στις δυο οπές και κάθε δεύτερη ημέρα θα γίνεται ανανέωση, ακολουθώντας την ίδια διαδικασία. The final ointment will be placed with the finger that will be washed with water and soap on the nose in both holes and every other day it will be renewed, following the same procedure.
Για την ευκολότερη χρήση της αλοιφής, θα χρησιμοποιηθεί ένα σωληνάριο με μια μακρά και λεπτή άκρη (ακροφύσιο) ώστε να μπορεί η αλοιφή να εισέρχεται και να τοποθετείται και στις δυο οπές τη μύτης με ευκολία. Η παρουσία του μονοκλονικού αντισώματος θα εξουδετερώσει τον ιό και στην περίπτωση που θα περάσει μικρή ποσότητα του ιού θα είναι χωρίς σοβαρά συμπτώματα και θα είναι επίσης, πολύ σπάνια περίπτωση. To make the ointment easier to use, a tube with a long and thin tip (nozzle) will be used so that the ointment can enter and be placed in both nostrils with ease. The presence of the monoclonal antibody will neutralize the virus and in the event that a small amount of the virus passes it will be without serious symptoms and it will also be a very rare case.
Εν κατακλείδι, στην παρούσα εφεύρεση παρουσιάζεται η παρασκευή μία αλοιφής που θα εμπεριέχει ποσότητα υδρόφιλης αλοιφής σε συνδυασμό ενός polyreactive μονοκλονικού ή ενός κλασικού μονοκλονικού αντισώματος σε ποσοστό στο 10%. Ο εύκολος τρόπος χρήσης της αλοιφής, θα διευκολύνει τον πληθυσμό της χώρας μας αλλά και των άλλων χωρών να την χρησιμοποιούν για την αποτελεσματική προστασία τους από τον κορωνοϊό COVID-19 ενώ η οικονομική επιβάρυνση των ατόμων πιθανόν να είναι μικρότερη των 5 ευρώ για τη κάλυψη του σωληνάριου που θα παράγεται από εταιρεία. In conclusion, the present invention presents the preparation of an ointment that will contain a quantity of hydrophilic ointment in combination with a polyreactive monoclonal or a classical monoclonal antibody at a rate of 10%. The easy way to use the ointment will make it easier for the population of our country and other countries to use it to effectively protect themselves from the COVID-19 coronavirus, while the financial burden on individuals is likely to be less than 5 euros to cover the tube to be produced by a company.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20200100756A GR1010195B (en) | 2020-12-30 | 2020-12-30 | Protection against covid-19 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20200100756A GR1010195B (en) | 2020-12-30 | 2020-12-30 | Protection against covid-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR1010195B true GR1010195B (en) | 2022-03-17 |
Family
ID=81388079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20200100756A GR1010195B (en) | 2020-12-30 | 2020-12-30 | Protection against covid-19 |
Country Status (1)
| Country | Link |
|---|---|
| GR (1) | GR1010195B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007034741A1 (en) * | 2005-09-22 | 2007-03-29 | Daikin Industries, Ltd. | Anti-viral agent, and method for treatment of virus-infected cell |
| WO2020160171A1 (en) * | 2019-01-29 | 2020-08-06 | Sanford Burnham Prebys Medical Discovery Institute | Topically formulated antibody compositions for reducing pathogen transmission and methods of using same |
-
2020
- 2020-12-30 GR GR20200100756A patent/GR1010195B/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007034741A1 (en) * | 2005-09-22 | 2007-03-29 | Daikin Industries, Ltd. | Anti-viral agent, and method for treatment of virus-infected cell |
| WO2020160171A1 (en) * | 2019-01-29 | 2020-08-06 | Sanford Burnham Prebys Medical Discovery Institute | Topically formulated antibody compositions for reducing pathogen transmission and methods of using same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Karshiboyevna et al. | Geographical aspects of the study of global pandemies | |
| McDonald | Getting the COVID‐19 pandemic into perspective: a nursing imperative | |
| Orsini et al. | Vaccine hesitancy, misinformation in the era of Covid-19: Lessons from the past | |
| GR1010195B (en) | Protection against covid-19 | |
| Habib et al. | Double trouble: COVID-19 vaccine misinformation amidst conflict in Ukraine | |
| Peet et al. | The chemical prophylaxis for poliomyelitis: The technic of applying zinc sulfate intranasally | |
| Machado | 100 years later, little has changed in Brazil: disinformation and pandemic | |
| Chinawa | Immunization dropout rates in Ihe, Awgu local government area, Enugu state, South East Nigeria: a 1 year review | |
| Nathanson | The human toll of viral diseases: past plagues and pending pandemics | |
| Riaz et al. | Islam and polio | |
| Akech et al. | COVID-19 Vaccination Uptake and Self-Reported Side Effects among Healthcare Workers in Mbale City Eastern Uganda | |
| BR102020007149A8 (en) | Uses of an anti-cgrp or anti-cgrp-r antibody or a fragment thereof to improve the most bothersome symptom (mbs) and global impression of change (pgic) associated with migraine | |
| Torales et al. | Attitudes towards the COVID-19 vaccine in the general paraguayan population | |
| McLaughlin et al. | Effectiveness of COVID-19 Vaccine Booster Dose Against COVID-19 During the SARS CoV-2 B. 1.1. 529 (Omicron) Wave-Alaska, December 2021–January 2022 | |
| Hadiyel et al. | A Clinical and Epidemiological Study of H1N1 Cases at Tertiary Care Hospital in Bhavnagar, Gujarat. | |
| Bara et al. | COVID 19 Vaccine Perception and Confidence Among Health Care Workers–An Analytic Cross Sectional Study, City of Harare, Zimbabwe, 2021 | |
| Wilder-Smith et al. | The role of influenza vaccine in healthcare workers in the era of severe acute respiratory syndrome | |
| Lepkowska | HPV immunisation: Moving toward a single dose? | |
| Singh et al. | Inter-State Analysis of COVID-19 Vaccination Status in India | |
| Rahayu | Perspectives of COVID-19 Vaccines Among Indonesians: A Thematic Content Analysis of Online Media | |
| Zareipour et al. | The Role of Health Literacy in COVID-19 Vaccine Hesitancy | |
| Mandavilli | First Documented Coronavirus Reinfection Reported in Hong Kong | |
| Hajje | A Meta-Analysis of Vaccination Hesitancy: the case of MMR and COVID 19 | |
| Ette et al. | Corona Virus Control Measures: Social Distancing Or Physical Distancing? | |
| Gürsoy et al. | Barriers, vaccine hesitancy and attitudes towards the to the covid-19 vaccine in Türkiye |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PG | Patent granted |
Effective date: 20220418 |